New rabies vaccine trial aims for safer shots
NCT ID NCT07338786
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing the safety of a freeze-dried human rabies vaccine in 80 healthy people aged 10 to 60. Participants receive the vaccine in different schedules, and researchers monitor for side effects for 30 days after the last dose. The goal is to see if the vaccine is safe enough to move into larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Lyophilized human rabies vaccine (human diploid cell)
- What this could lead to
- If successful, this could support a safer and more flexible rabies vaccination schedule for both adults and adolescents.
- What could go wrong
- This is a very early Phase 1 safety trial with only 80 participants, so it cannot prove the vaccine prevents rabies. Side effects may still emerge.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RABIESPREVENTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jiangsu CDC
Xuzhou, Jiangsu, China